Acer Therapeutics Inc. announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer. Dr. Quartel will oversee Acer's clinical development, medical affairs, regulatory and other scientific and medical functions. Dr. Quartel joins Acer Therapeutics from Adamas Pharmaceuticals, a company focused on drug discovery, development, and delivery of treatments for neurological diseases, where he served as Chief Medical Officer since 2020.

In his role at Adamas, Dr. Quartel oversaw research and development, as well as medical affairs and regulatory functions. Prior to Adamas, he served as the Group Vice President, Global Medical Affairs, at BioMarin Pharmaceuticals Inc. where he led the launch of six treatments for rare disease or rare genetic disorders, including KUVAN, VIMIZIM and Brineura.